We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$385M
AUM Growth
-$76.2M
Cap. Flow
-$70.4M
Cap. Flow %
-18.28%
Top 10 Hldgs %
44.6%
Holding
124
New
35
Increased
20
Reduced
21
Closed
33

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$16.8M
2
LLY icon
Eli Lilly
LLY
+$15.1M
3
SHPG
Shire pic
SHPG
+$13.7M
4
AMGN icon
Amgen
AMGN
+$13.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.79M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.6M
2
BIIB icon
Biogen
BIIB
+$18M
3
ORA icon
Ormat Technologies
ORA
+$13.3M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.65M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.41M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Technology 4.38%
3 Communication Services 1.71%
4 Consumer Discretionary 1.16%
5 Financials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
26
DELISTED
Adamas Pharmaceuticals
ADMS
$4.09M 1.06%
270,000
– –
CLCD
27
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$4.09M 1.06%
500,137
+221,800
+80% +$1.49M
TSRO
28
CALL
DELISTED
TESARO, Inc.
TSRO
$3.78M 0.98%
+450
New +$20.1K
KERX
29
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.73M 0.97%
+562,900
New +$3.15M
CHTR icon
30
Charter Communications
CHTR
$17.3B
$3.67M 0.95%
16,065
+135
+0.8% +$29K
GWPH
31
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.66M 0.95%
+40,000
New +$3.37M
BCOM
32
DELISTED
B Communications Ltd
BCOM
$3.56M 0.92%
+148,861
New +$3.86M
MGNX icon
33
MacroGenics
MGNX
$235M
$3.51M 0.91%
130,000
-23,000
-15% -$519K
ASND icon
34
Ascendis Pharma A/S
ASND
$16B
$3.47M 0.9%
+261,800
New +$4.03M
ALNY icon
35
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.33M 0.86%
+600
New +$37.8K
RDUS
36
DELISTED
Radius Health, Inc.
RDUS
$3.31M 0.86%
90,000
– –
SAGE
37
CALL
DELISTED
Sage Therapeutics
SAGE
$3.01M 0.78%
+1,000
New +$33.3K
EIGR
38
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.99M 0.78%
5,024
+107
+2% +$65K
GOOGL icon
39
Alphabet (Google) Class A
GOOGL
$4.36T
$2.93M 0.76%
83,240
-30,360
-27% -$1.11M
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.91M 0.76%
88,659
+43,420
+96% +$1.59M
GWPH
41
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.84M 0.74%
+310
New +$26.1K
V icon
42
Visa
V
$684B
$2.82M 0.73%
37,966
-29,403
-44% -$2.3M
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
$2.81M 0.73%
112,500
+50,000
+80% +$1.35M
CLVS
44
DELISTED
Clovis Oncology, Inc.
CLVS
$2.74M 0.71%
200,000
+105,500
+112% +$1.54M
TVTX icon
45
Travere Therapeutics
TVTX
$5.2B
$2.67M 0.69%
+150,000
New +$2.43M
KITE
46
DELISTED
Kite Pharma, Inc.
KITE
$2.5M 0.65%
50,000
– –
ACOR
47
DELISTED
Acorda Therapeutics
ACOR
$2.5M 0.65%
817
+209
+34% +$680K
GNMX
48
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.5M 0.65%
+450,000
New +$2.36M
FPRX
49
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.48M 0.64%
60,000
-20,000
-25% -$870K
RLYP
50
DELISTED
RELYPSA INC COM
RLYP
$2.4M 0.62%
+130,000
New +$2.28M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sphera Funds Management held 124 positions worth $385M, down 17% from $461M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $70.4M in Q2 2016, closing 33 positions and reducing 21 holdings. Its most notable exit was Ormat Technologies, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 62% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in GSK worth $6.39M.

  • Sphera Funds Management's largest Q2 2016 buy was GSK: 318,630 shares worth $6.39M.
  • Sphera Funds Management added most to Shire pic in Q2 2016, an estimated $13.7M increase.
  • Sphera Funds Management's biggest Q2 2016 reduction was Pfizer, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited Ormat Technologies in Q2 2016, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $385M portfolio in Q2 2016.
  • Sphera Funds Management opened 35 new positions and closed 33 in Q2 2016.
  • Sphera Funds Management's portfolio value fell 17% quarter-over-quarter to $385M.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.